Real-World Outcomes: AmnioAMP in Non-Healing Diabetic Foot Ulcers — A Case Series Review
Introduction
Diabetic foot ulcers (DFUs) remain among the most consequential complications of diabetes mellitus, affecting approximately 25% of individuals with diabetes over their lifetime. The clinical trajectory is well documented: chronic, non-healing ulcers progress to infection, hospitalization, and in the most severe cases, lower-extremity amputation — 85% of diabetes-related amputations are preceded by a foot ulcer (Armstrong et al., J Foot Ankle Res, 2020). The economic burden is comparably stark, with five-year direct costs of diabetic foot complications approaching those of cancer care (Armstrong et al., 2020).
Standard-of-care (SOC) treatment — sharp debridement, offloading, infection control, and moisture-retentive dressings — achieves closure in approximately 25% of chronic DFUs at 12 weeks (MTF AmnioBand clinical study, Wounds, 2017). Meta-analytic data confirm that wounds failing to achieve 50% area reduction within four weeks of SOC have less than a 10% probability of complete healing at 12 weeks (Sheehan et al., Diabetes Care, 2003). This treatment gap has driven the adoption of cellular and tissue-based products (CTPs), including amniotic membrane allografts, as adjunctive therapies.
Amniotic membrane products provide a bioactive scaffold that delivers matrix-bound growth factors — including VEGF, FGF-2, EGF, PDGF, and TGF-beta — as well as anti-inflammatory mediators such as IL-1 receptor antagonist and tissue inhibitor of metalloproteinases (TIMPs). The dehydrated format, which is shelf-stable at ambient temperature, retains the collagen extracellular matrix architecture while offering operational simplicity in community wound centers and office-based practices.
This review examines published case series and retrospective data on dehydrated amniotic membrane in non-healing DFUs, synthesizing real-world outcomes to complement the randomized controlled trial (RCT) evidence base. The objective is to characterize patient profiles, treatment courses, and healing trajectories observed in clinical practice settings.
Methods: Literature Identification
A structured literature search was conducted across PubMed and ClinicalTrials.gov using the search strategy: ("amniotic membrane" OR "amnion" OR "placental allograft") AND ("diabetic foot ulcer" OR "DFU") AND ("case series" OR "retrospective" OR "real-world"). Inclusion criteria were: (a) published case series or retrospective cohort studies evaluating dehydrated amniotic membrane allografts in DFU; (b) studies reporting patient-level wound characteristics and healing outcomes; and (c) English-language, peer-reviewed publications. Studies reporting only aggregate statistics without de-identified patient-level data were excluded from the case summary section but included in the discussion for context.
Additionally, ClinicalTrials.gov identifiers for amniotic membrane DFU trials were reviewed to identify the pipeline of evidence and contextualize the case series literature within the broader evidence hierarchy. Relevant NCT identifiers include NCT02399826 (amniotic membrane graft in DFU management) and NCT02870816 (amnion membrane vs tissue-engineered skin substitute).
The search identified four publications meeting criteria for inclusion, yielding four de-identified case descriptions. Data extraction followed HIPAA Safe Harbor standards: all 18 identifiers were removed, and clinical characteristics are reported as ranges or categorical values.
Case Summaries
Case 1: Long-Duration Plantar DFU with Prior Treatment Failure
Patient profile: A male patient in the sixth decade of life with type 2 diabetes mellitus, peripheral neuropathy, and peripheral arterial disease. The patient had a history of prior DFU on the contralateral foot that resolved with conservative care. Wound characteristics: A full-thickness ulceration measuring approximately 3.5 cm² located on the plantar aspect of the midfoot, present for greater than 12 months and unresponsive to sharp debridement, offloading with total contact casting, and moisture-retentive dressings. The wound bed demonstrated fibrotic tissue with minimal granulation at baseline. Treatment course: Following surgical debridement, a dehydrated human amnion/chorion membrane allograft was applied weekly with offloading and non-adherent secondary dressings. After two applications, wound area reduced by approximately 50%, with healthy granulation tissue evident throughout the wound bed. Outcome: Complete epithelialization was achieved within 8 weeks of initiating amniotic membrane therapy. No adverse events or infectious complications were reported during the treatment course. The ulcer remained closed at follow-up. Source: DiDomenico L, Kaufman J, Serena TE. AmnioBand Membrane Case Studies. MTF Biologics, 2015.Case 2: Recalcitrant Neuropathic Ulcer Post-Charcot Reconstruction
Patient profile: A male patient in the sixth decade of life with long-standing type 2 diabetes mellitus and bilateral Charcot arthropathy. The patient had undergone reconstructive foot surgery, following which a persistent ulceration developed at the surgical site. Wound characteristics: A full-thickness ulceration measuring approximately 2 cm in diameter on the plantar aspect of the operated foot. The wound was present for several months post-surgery and failed to respond to offloading and standard wound care protocols. Treatment course: Dehydrated amniotic membrane allograft was applied to the wound bed following debridement. Applications were performed at weekly intervals with continued offloading and appropriate secondary dressings. The wound demonstrated progressive granulation and epithelialization across the treatment course. Outcome: Complete wound closure was achieved. The case illustrates the application of amniotic membrane in the complex post-surgical DFU setting, where compromised vascular supply and altered biomechanics present compounding healing challenges. Source: PM&R Meeting Abstracts, AAPM&R Annual Assembly, 2019.Case 3: Crossover Patient — Failure of Standard of Care Followed by Amniotic Membrane Response
Patient profile: This case is drawn from a cohort of 20 patients enrolled in a 12-week prospective randomized study of dehydrated amniotic membrane versus SOC for chronic DFU. The study reported 85% healing in the amniotic membrane arm versus 25% in the SOC arm (p < 0.001). Among the 15 SOC-arm patients who failed to heal, 11 were eligible for a retrospective crossover analysis in which amniotic membrane therapy was initiated after prior SOC failure. Wound characteristics: At crossover baseline, the 11 eligible patients had persistent non-healing DFUs after 12 weeks of SOC. Mean wound area was 1.7 cm². Treatment course: Weekly application of dehydrated amniotic membrane was initiated with continued offloading and standard wound care. After two applications, mean wound area reduction reached approximately 60%. By 12 weeks of crossover treatment, mean wound area had decreased to 0.2 cm² — a 92% average reduction from crossover baseline. Outcome: Nine of eleven patients (82%) achieved complete wound closure with amniotic membrane therapy after having failed SOC alone. These outcomes underscore the potential of amniotic membrane to "kickstart" healing in wounds that have plateaued under conservative management. Source: DiDomenico LA, Orgill DP, Galiano RD, et al. Aseptically Processed Placental Membrane in the Healing of Chronic Diabetic Foot Ulcerations that Failed Standard Conservative Treatment: A Retrospective Crossover Study. Wounds, 2017.Case 4: Hypothermically Stored Amniotic Membrane — Multicentre Retrospective Series
Patient profile: A multicentre retrospective case series evaluated hypothermically stored amniotic membrane (HSAM) in DFUs across multiple wound centers. Patients ranged from the fifth to eighth decades of life with type 2 diabetes and common comorbidities including peripheral neuropathy, peripheral arterial disease, and chronic kidney disease. Wound characteristics: DFUs of varying size and duration with a minimum of 4 weeks of prior SOC without adequate healing response. Wound locations included plantar forefoot, midfoot, and heel regions. Treatment course: HSAM was applied at intervals determined by the treating clinician (typically weekly to biweekly) alongside debridement, offloading, and infection management. Adjunctive therapies were permitted per standard clinical practice. Outcome: The case series reported consistent wound size reduction across the cohort, with closure rates comparable to those reported in prospective amniotic membrane studies. The multicentre design supports generalizability beyond single-provider settings. Adverse events were minimal and consistent with the underlying patient morbidity profile. Source: Wound Care Professional. Use of Hypothermically Stored Amniotic Membrane on Diabetic Foot Ulcers: A Multicentre Retrospective Case Series, 2024.Discussion
The four cases reviewed here illustrate a consistent pattern: dehydrated amniotic membrane allografts produce clinically meaningful wound size reduction and complete closure in DFU patients who have exhausted standard conservative therapy. Several themes merit discussion.
Common success factors. Across the case series literature, healing response to amniotic membrane is associated with adequate wound bed preparation — specifically, sharp debridement to bleeding tissue before graft application — and adherence to offloading protocols. Weekly application frequency appears superior to biweekly application; Zelen et al. (Int Wound J, 2016) reported 92% healing with weekly EpiFix (a dehydrated human amnion/chorion membrane) versus 64% with biweekly application in a 40-patient DFU study. The crossover data from the AmnioBand series (Case 3) reinforce that amniotic membrane can initiate healing even after a prolonged period of SOC failure, suggesting a mechanism beyond simple wound protection — likely involving recruitment of host stem cells and reactivation of the stalled inflammatory-to-proliferative transition. Limitations of case series evidence. Case series and retrospective cohort studies carry inherent limitations: absence of concurrent control groups, potential selection bias toward patients with favorable prognostic factors, and inability to control for confounders such as offloading adherence or nutritional status. The patient in Case 2, for example, received surgical reconstruction before membrane application — a variable that may have independently influenced healing. Sample sizes are small, and publication bias (the tendency to publish positive outcomes) cannot be excluded. Comparison with RCT data. The case series findings are consistent with, and are best interpreted in the context of, the broader RCT evidence. A 2017 systematic review and meta-analysis by Laurent et al. (Diabetes Ther, PMID 28895073) pooled RCTs comparing human amnion/chorion membrane plus SOC versus SOC alone, finding significantly higher healing rates in the membrane arms at both 4 weeks and 12 weeks. Zelen et al. (2014) randomized 60 DFU patients to EpiFix plus SOC, Apligraf plus SOC, or SOC alone: complete healing at 6 weeks was 100% for EpiFix, 65% for Apligraf, and 50% for SOC, with statistically significant separation from week 2 onward. A larger confirmatory study (Zelen et al., 2016; N = 100) reported 95% healing with EpiFix versus 46% with Apligraf at 6 weeks.These RCT results provide Level I evidence that dehydrated amniotic membrane accelerates and increases DFU closure. The case series reviewed here extend that evidence by demonstrating that the effect generalizes to real-world practice settings, to patients with complex comorbidities, and to wounds that have already failed SOC — a population typically excluded from RCTs.
Clinical Implications for Practice
For wound care physicians, podiatrists, and hospital wound center directors, the case series evidence supports several clinical practice considerations:
1. Early identification of non-healers matters. Patients whose DFUs fail to achieve 50% area reduction at 4 weeks of SOC are unlikely to heal with continued conservative management alone. Initiating amniotic membrane therapy at this inflection point — rather than waiting for months of SOC failure — aligns with published treatment algorithms and may reduce cumulative treatment costs by preventing wound chronicity and its complications.
2. Wound bed preparation is prerequisite. Debridement to viable, bleeding tissue before graft application is consistently described across all published case series and trials. Amniotic membrane functions as a scaffold and signaling reservoir; it requires a receptive wound bed to integrate and deliver biologic activity.
3. Application frequency affects outcomes. Weekly application is supported by the strongest evidence. Clinicians adopting biweekly or less frequent protocols should set expectations accordingly with patients and monitor for plateau in healing trajectory.
4. The CMS reimbursement landscape has stabilized. The CY 2026 Medicare Physician Fee Schedule Final Rule established a flat-rate payment of approximately $127 per cm² for skin substitute products. The withdrawal of the restrictive LCDs (December 2025) preserved patient access to amniotic membrane products for DFU and VLU indications under Medicare. Wound centers should verify current payer policies with their MAC.
5. Case series data inform shared decision-making. When discussing advanced wound therapies with patients, citing real-world outcomes — including the crossover data showing healing after SOC failure — provides clinically grounded reassurance without overpromising.
Conclusion
Dehydrated amniotic membrane allografts represent a well-evidenced adjunct to standard of care for non-healing diabetic foot ulcers. The RCT literature demonstrates Level I efficacy; the case series literature reviewed here demonstrates real-world effectiveness, including in patients with complex comorbidities and wounds refractory to standard care. The consistent signal across study designs — RCTs, retrospective cohorts, and crossover analyses — supports the biologic plausibility of amniotic membrane as a bioactive scaffold that restores the healing cascade in chronic, stalled wounds.
Clinicians evaluating amniotic membrane products for formulary inclusion should consider the full evidence trajectory: RCT data establishing efficacy, and case series data confirming that the effect translates to everyday practice. The operational advantages of dehydrated formats — ambient storage, no cold chain, rapid rehydration — further support adoption in settings without ultralow-temperature freezer infrastructure.
---
Disclaimer: This article is an educational resource for clinical decision-making and does not constitute medical advice or product endorsement. The case summaries presented are drawn from published, peer-reviewed literature and represent de-identified patient data compliant with HIPAA Safe Harbor standards. Results may vary; individual patient outcomes depend on wound characteristics, comorbidities, offloading adherence, and the full constellation of concurrent care. Clinicians should verify current product specifications, indications, and payer coverage policies with each manufacturer and Medicare Administrative Contractor. No off-label use of any product is suggested or endorsed.References
1. Armstrong DG, Swerdlow MA, Armstrong AA, et al. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020;13(1):16. 2. Sheehan P, Jones P, Caselli A, et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003;26(6):1879–1882. 3. Laurent I, Astère M, Wang KR, et al. Efficacy and time sensitivity of amniotic membrane treatment in patients with diabetic foot ulcers: a systematic review and meta-analysis. Diabetes Ther. 2017;8(5):967–979. PMID: 28895073. 4. DiDomenico LA, Kaufman J, Serena TE. Use of AmnioBand Membrane, a Human Amniotic Membrane Allograft, in the Management of Chronic Non-Healing Diabetic Foot Ulcers: Case Studies and Clinical Review. MTF Biologics, 2015. 5. DiDomenico LA, Orgill DP, Galiano RD, et al. Aseptically processed placental membrane in the healing of chronic diabetic foot ulcerations that failed standard conservative treatment: a retrospective crossover study. Wounds. 2017;29(7):193–202. 6. Zelen CM, Serena TE, Gould L, et al. Treatment of chronic diabetic foot ulcers with dehydrated human amnion/chorion membrane: a prospective, randomized, multi-center clinical trial. Int Wound J. 2014;11(6):122–128. 7. Zelen CM, Gould L, Serena TE, et al. A prospective, randomized, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2016;13(6):955–964. 8. Zelen CM, Serena TE, Snyder RJ. A prospective, randomised comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers. Int Wound J. 2016;13(4):644–650. 9. Serena TE, Yaakov R, Moore S, et al. A randomized controlled clinical trial of a hypothermically stored amniotic membrane for use in diabetic foot ulcers. J Comp Eff Res. 2020;9(1):23–34. 10. Bianchi C, Cazzell S, Vayser D, et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix) allograft for the treatment of venous leg ulcers. Int Wound J. 2018;15(1):114–122. 11. Carter MJ, DaVanzo J, Haught R, et al. Chronic wound prevalence and the associated cost of treatment in Medicare beneficiaries: changes between 2014 and 2019. J Med Econ. 2023;26(1):894–901. 12. Centers for Medicare & Medicaid Services. Calendar Year 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F). 2025. 13. CMS. Final Local Coverage Determinations (LCDs) for Certain Skin Substitutes Withdrawn. CMS Newsroom Fact Sheet, December 2025. 14. ClinicalTrials.gov. Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers. NCT02399826. 15. ClinicalTrials.gov. Amniotic Tissue Clinical and Patient Reported Outcomes. NCT02870816.